Clinical Trial Phases I to IV: Purpose, Sample Size & Endpoints

Why Clinical Trial Phases Matter for Regulatory Biostatistical Programming

Clinical SAS programmers write the validation, transformation, and summary scripts for regulatory submission (NDA / BLA) to regulatory agencies like the FDA and EMA.

Standard Syntax, Derivation & Framework Pattern

/* Flagging Treatment Phases & Cohort Assignment */
DATA work.trial_cohorts;
    SET raw.dm;
    LENGTH Phase_Label $25;
    SELECT (STUDYPH);
        WHEN ('PH1') Phase_Label = 'Phase I: Safety/PK';
        WHEN ('PH2') Phase_Label = 'Phase II: Proof of Concept';
        WHEN ('PH3') Phase_Label = 'Phase III: Pivotal Trial';
        OTHERWISE    Phase_Label = 'Post-Market Observational';
    END;
RUN;

Core Rules & Certification Takeaways

• Phase I focuses primarily on pharmacokinetics (PK), maximum tolerated dose (MTD), and toxicity profile.
• Phase II evaluates therapeutic biological activity and optimal dosing regimens in targeted patient populations.
• Phase III provides pivotal, multi-center, double-blind randomized evidence required for FDA approval.
• Phase IV monitors real-world adverse drug reactions (ADRs) and long-term pharmacovigilance.

🔗 Related Architectural Concepts & Next Steps

Deepen your mastery with connected topics across our curriculum and knowledge hubs.

Frequently Asked Questions (FAQ)